Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease

Onkologie

Volumn 29, Issue 11, 2006, Pages 534-540

  Bergner, Raoul ^a   Diel, Ingo J ^b   Henrich, Dirk ^a   Hoffmann, Martin ^a   Uppenkamp, Michael ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b CGG Klinik   (Germany)

Author keywords

Bisphosphonates; Clinical trial; Ibandronate; Pamidronate; Preclinical; Renal safety; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CREATININE; IBANDRONIC ACID; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; FIBROSING ALVEOLITIS; HUMAN; KIDNEY TUBULE NECROSIS; NEPHROTOXICITY; PROSTATE CANCER; REVIEW;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33750293909     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096056     Document Type: Review

References (51)

1. Finley RS: Bisphosphonates in the treatment of bone metastases. Semin Oncol 2002;29(suppl 4):132-138.
2. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee, GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S; American Society of Clinical Oncology: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057.
3. Russell RG, Rogers MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106.
4. Pavlakis N, Stockier M: Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2002;1:CD003474.
5. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
6. Lipton A, Seaman J, Zheng M: Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Bone 2004;24(suppl 1):S62.
7. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B; MF Study Group: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-1405 (corrigendum in Ann Oncol 2004;15:180).
8. Perazella MA, Reilly RF: Chronic kidney disease: a new classification and staging system. Hosp Physician 2003;45:18-22; www.turner-white.com.
9. Corso A, Zappasodi P, Lazzarino M: Urinary proteins and renal dysfunction in patients with multiple myeloma. Biomed Pharmacother 2002;56:139-143.
10. Kintzel PE: Anticancer drug-induced kidney disorders. Incidence, prevention and management. Drug Saf 2001;24:19-38.
11. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003a;98:1735-1744.
12. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
13. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P Zheng M, Urbanowitz G, Reitsma D, Seaman JJ: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumours: a phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumours Study Group. J Clin Oncol 2003b;21:3150-3157.
14. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumours: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
15. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
16. Conte P, Guarneri V: Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9(suppl 4):28-37.
17. Diel I, Body JJ, Bergström B: Renal safety of intravenous (i.v.) ibandronate for up to 4 years of treatment in patients with metastatic bone disease. Ann Oncol 2004;15(suppl 3):iii224.
18. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001;12:1164-1172.
19. Desikan R, Veksler Y, Raza S, Stokes B, Sabir T, Li ZJ, Jagannath S: Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002;119:496-449
20. Banerjee D, Asif A, Striker L, Preston RA, Bougoignie JJ, Roth D: Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003;41:E18.
21. Lyubimova NV, Kushlinsky NE, Lichinitser MR, Schlosser K: Renal safety of intravenous ibandronate in breast cancer patients with metastatic bone disease. Clin Drug Invest 2003;23:707-716.
22. Neugebauer G, Koehler W, Akinkunmi L, Pinner J, Kletzl H, Banken L: Influence of peak ibandronic acid concentrations after 6mg i.v. administration with shortened infusion time (15 and 30 minutes) on renal safety in man. J Clin Oncol 2001;20(suppl):122A, abstr 486.
23. Body JJ, Lichinitser M, Andreeva N, Budde M, Bergström B: Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: results of an open-label study. J Clin Oncol 2004;23(suppl):60, abstr 735.
24. Mancini I, Dumon JC, Body JJ: Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004;22:3587-3592.
25. Ohlmann C, Heidenreich A: Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer 2003;11:396.
26. Heidenreich A, Ohlmann C, Olbert P, Hegele A: High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 2003;1(suppl 5):S270.
27. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Breierova L, Smith M, Neary M, Duh MS: A comparison of logistic regression and cox proportional hazards models for identification of risk factors for renal impairment in hormone refractory prostate cancer (HRPC) patients with bone metastases (BM) treated with zoledronic acid (ZA). International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 8th Annual European Congress 6-8 November 2005, Florence, Italy.
28. Berenson JR: Zoledronic acid clinical experience. Webcast of the 10th International Myeloma Workshop, Sydney, Australia, 10-14 April 2005; www.zometa.com/hcp/tools/web_cast.jsp.
29. Johnson K, Gable P, Kaime EM, Luiken G, Castillos T, Hu J: Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. J Clin Oncol 2003;22(suppl):738, abstr 2968.
30. Chang JT, Green L, Beitz J: Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-1679.
31. Bergner R, Henrich DM, Hoffmann M, et al.: Renal safety of ibandronate in multiple myeloma patients with renal deterioration. Cancer Treat Rev 2005;31(suppl 1):S45.
32. Tralongo P, Repetto L, Di Mari A, Mauceri G, Bollina R, Ferrau F, Conti G: Safety of long-term administration of bisphosphonates in elderly cancer patients. Oncology 2004;67:112-116.
33. Henrich D, Bergner R, Hoffmann M, et al.: Renal safety of ibandronate in elderly myeloma patients with pre-existing renal deterioration. Accepted for presentation at the sixth meeting of the International Society of Geriatric Oncology, Geneva, Switzerland, 2005.
34. Stein SH, Davidson R, Tweed A, Demichele A, Domceck S, Fox K, Cohen D: Renal dysfunction with iv bisphosphonates in patients with metastatic breast cancer. J Clin Oncol 2003;22(suppl):745, abstr 2997.
35. Mazj S, Lichtman SM: Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics. J Clin Oncol 2004;22(suppl):8039.
36. Cal JC, Daley-Yates PT: Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Toxicology 1990;65:179-197.
37. Lin JH, Chen IW, Deluna FA, Hichens M: Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 1992;20:608-613.
38. Kino I, Kato Y, Lin JH, Sugiyama Y: Renal handling of bisphosphonate alendronate in rats. Biopharm Drug Dispos 1999;20:193-198.
39. Ullrich KJ, Rumrich G, Burke TR, Shirazi-Beechey SP, Lang H: Interaction of alkyl/arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule. J Pharmacol Exp Ther 1997;283:1223-1229.
40. Fleisch H: Bisphosphonates in Bone Disease: From the Laboratory to the Patient; 4th ed. New York and London, Parthenon Publishing Group Ltd, 2000.
41. Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcemia of malignancy. Drug Saf 1999;21:389-406.
42. Pfister T, Atzpodien E, Bauss F: The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate acid following single and intermittent administration in rats. Toxicology 2003;191:159-167.
43. Pfister T, Bauss F, Body JJ: The risk of cumulative renal effects of intravenous (i.v.) bisphosphonates. Ann Oncol 2004;15(suppl 3):iii226, abstr 859P.
44. Pfister T, Atzpodien E, Bohrmann B, Bauss FF: Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 2005;97:374-381.
45. Bauss F, Endele R, Besenfelder E, Hoelck J-P: Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection. Calcif Tissue Int 2002;70:289-290, abstr P-128.
46. Bauss F, Russell RG: Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423-433.
47. Launay-Vacher V, Izzedine H, Rey J-B, Rixe O, Chapalain S, Nourdine S, Paci A, Bourget P, Deray G: Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 2004;10:CR209-212.
48. Swedko PJ, Clark HD, Paramsothy K, Akbari A: Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003;163:356-360.
49. National Kidney Foundation, Inc.: Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-266.
50. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
51. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.